Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates.

Zennou V, Bieniasz PD.

Virology. 2006 May 25;349(1):31-40. Epub 2006 Feb 7.

2.

Biochemical differentiation of APOBEC3F and APOBEC3G proteins associated with HIV-1 life cycle.

Wang X, Dolan PT, Dang Y, Zheng YH.

J Biol Chem. 2007 Jan 19;282(3):1585-94. Epub 2006 Dec 1.

5.

APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.

Holmes RK, Koning FA, Bishop KN, Malim MH.

J Biol Chem. 2007 Jan 26;282(4):2587-95. Epub 2006 Nov 22.

6.

Further investigation of simian immunodeficiency virus Vif function in human cells.

Gaddis NC, Sheehy AM, Ahmad KM, Swanson CM, Bishop KN, Beer BE, Marx PA, Gao F, Bibollet-Ruche F, Hahn BH, Malim MH.

J Virol. 2004 Nov;78(21):12041-6.

7.

Different interaction between HIV-1 Vif and its cellular target proteins APOBEC3G/APOBEC3F.

Nagao T, Yamashita T, Miyake A, Uchiyama T, Nomaguchi M, Adachi A.

J Med Invest. 2010 Feb;57(1-2):89-94.

8.

Antiviral roles of APOBEC proteins against HIV-1 and suppression by Vif.

Romani B, Engelbrecht S, Glashoff RH.

Arch Virol. 2009;154(10):1579-88. doi: 10.1007/s00705-009-0481-y. Epub 2009 Aug 12. Review.

PMID:
19669862
9.

Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication.

Zheng YH, Irwin D, Kurosu T, Tokunaga K, Sata T, Peterlin BM.

J Virol. 2004 Jun;78(11):6073-6.

10.

A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action.

Mangeat B, Turelli P, Liao S, Trono D.

J Biol Chem. 2004 Apr 9;279(15):14481-3. Epub 2004 Feb 13.

11.

A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif).

Schröfelbauer B, Chen D, Landau NR.

Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3927-32. Epub 2004 Feb 20.

12.

Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies.

Wichroski MJ, Robb GB, Rana TM.

PLoS Pathog. 2006 May;2(5):e41. Epub 2006 May 12.

13.
14.

APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo.

Liddament MT, Brown WL, Schumacher AJ, Harris RS.

Curr Biol. 2004 Aug 10;14(15):1385-91.

16.

APOBEC deaminases as cellular antiviral factors: a novel natural host defense mechanism.

Franca R, Spadari S, Maga G.

Med Sci Monit. 2006 May;12(5):RA92-8. Review.

PMID:
16641889
17.

Identification of 81LGxGxxIxW89 and 171EDRW174 domains from human immunodeficiency virus type 1 Vif that regulate APOBEC3G and APOBEC3F neutralizing activity.

Dang Y, Davis RW, York IA, Zheng YH.

J Virol. 2010 Jun;84(11):5741-50. doi: 10.1128/JVI.00079-10. Epub 2010 Mar 24.

18.

Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation.

Pace C, Keller J, Nolan D, James I, Gaudieri S, Moore C, Mallal S.

J Virol. 2006 Sep;80(18):9259-69. Erratum in: J Virol. 2007 Aug;81(16):8843-5.

19.

Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.

He Z, Zhang W, Chen G, Xu R, Yu XF.

J Mol Biol. 2008 Sep 12;381(4):1000-11. doi: 10.1016/j.jmb.2008.06.061. Epub 2008 Jun 28.

PMID:
18619467
20.

Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family.

Dang Y, Wang X, Esselman WJ, Zheng YH.

J Virol. 2006 Nov;80(21):10522-33. Epub 2006 Aug 18. Erratum in: J Virol. 2011 May;85(10):5243.

Supplemental Content

Support Center